Cassava Sciences Inc (NASDAQ:SAVA)
| 45.53 Delayed Data As of Oct 22 |  -0.85 / -1.83%Today’s Change | 6.70 Today|||52-Week Range 146.16 | +567.60% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $1.8B |
Company Description
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Contact Information
Cassava Sciences, Inc. 7801 North Capital of Texas Highway Austin Texas 78731 |
Employees
Shareholders
| Individual stakeholders | 5.65% |
| Mutual fund holders | 14.01% |
| Other institutional | 13.53% |
Top Executives
| Remi Barbier | Chairman, President & Chief Executive Officer |
| Nadav Friedmann | Director, Chief Operating & Medical Officer |
| Eric J. Schoen | Chief Financial Officer |
| James W. Kupiec | Chief Clinical Development Officer |
| Michael Zamloot | Senior Vice President-Technical Operations |
